Research programme - becaplermin biosimilar - BioSavita

Drug Profile

Research programme - becaplermin biosimilar - BioSavita

Alternative Names: Becaplermin biosimilar - BioSavita; PDGF BB biosimilar

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator BioSavita
  • Class Blood proteins; Growth factors; Recombinant proteins
  • Mechanism of Action Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetic foot ulcer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Diabetic-foot-ulcer in USA (Topical)
  • 06 May 2013 Research programme - becaplermin biosimilar - BioSavita is available for licensing as of 06 May 2013. http://biosavita.com/
  • 02 May 2013 Early research in Diabetic foot ulcer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top